Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Greenwich Lifesciences Inc (GLSI) stock has reached a 52-week low, trading at $9.05, with InvestingPro data showing the RSI indicating oversold territory. The stock’s beta of 3.32 suggests significantly higher volatility than the broader market. This significant downturn reflects a broader trend for GLSI, which has seen its stock value decrease by 47.23% over the past year. While investors closely monitor the company’s performance, InvestingPro analysis reveals strong liquidity with a current ratio of 6.91, indicating solid short-term financial stability. The 52-week low serves as a critical indicator for the company’s short-term outlook and may influence its efforts to regain market confidence. Get access to 8 additional exclusive InvestingPro Tips to better understand GLSI’s market position.
In other recent news, Greenwich LifeSciences has reported significant developments in its Phase III FLAMINGO-01 clinical trial for the immunotherapy GLSI-100. The company announced that the trial has not shown any serious adverse events related to the drug, with the Data Safety Monitoring Board recommending the study’s continuation without modifications. Preliminary safety data aligns with Phase IIb results, indicating GLSI-100 is well-tolerated. The trial has also expanded its non-HLA-A02 arm to 250 patients, following approvals from both EU and US regulators, potentially leading to additional marketing pathways.
Furthermore, the company has initiated clinical sites in Germany, partnering with the German Breast Group to involve approximately 38 sites. This expansion is part of a broader strategy to activate more than 150 sites globally. The trial aims to evaluate the safety and efficacy of GLSI-100 in preventing breast cancer recurrences among HER2 positive patients. CEO Snehal Patel expressed satisfaction with the trial’s momentum and interest, emphasizing the potential for analyzing open label HLA data.
Greenwich LifeSciences continues to focus on developing its manufacturing and regulatory strategy for GLSI-100 in both the US and Europe. The company is also exploring subgroup analyses based on HLA-A combinations, which may inform initial commercial strategies. The trial’s interim analysis is planned after 14 of the required 28 events have occurred, aiming to detect a hazard ratio of 0.3 in invasive breast cancer-free survival.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.